NFlection was founded with the mission of developing proprietary, novel compounds that are highly selective mitogen-activated protein kinase kinase (MEK) inhibitors to mitigate or treat cutaneous neurofibromas in neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, congenital birthmarks, and other RAS-mediated skin conditions. Our first proprietary MEK inhibitor, NFX-179, is formulated in a cosmetically elegant gel that is applied topically, enabling high local drug concentration in the skin leading to local suppression of the Ras/Raf/MEK/ERK pathway that drives the pathology of cutaneous neurofibromas in neurofibromatosis type 1. NFX-179 is a metabolically labile “soft drug” that is rapidly broken down in the bloodstream, so it no longer has the ability to inhibit MEK systemically.

NFlection submitted an IND Application with the Food and Drug Administration and has completed Phase 2a and Phase 2b studies in patients with neurofibromatosis type 1 and cutaneous neurofibromas.